Comparison of Cardiovascular Outcomes Between Chlorthalidone and Hydrochlorothiazide in Hypertensive Patients

Overview

Journal J Clin Hypertens (Greenwich)

Specialty Cardiology & Vascular Diseases

Date 2025 Feb 17

PMID 39957722

Authors

Subin Lim

Ju Hyeon Kim

Seungmi Oh

Soon Jun Hong

Cheol Woong Yu

Hyung Joon Joo

Yong Hyun Kim

Eung Ju Kim

Affiliations

Soon will be listed here.

Abstract

Chlorthalidone (CLTD) and hydrochlorothiazide (HCTZ) are widely used thiazide diuretics for hypertension management. This study aimed to evaluate and compare the cardiovascular outcomes of patients treated with CLTD versus HCTZ. This multicenter, retrospective cohort study utilized data from the Korea University Medical Center, derived from electronic health records. A total of 14 257 hypertensive patients treated with either CLTD (n = 1920) or HCTZ (n = 12 337) were identified. Patients were matched 1:1 using propensity scores, resulting in 1606 patients in each treatment group. Demographic and clinical characteristics, incidence of major adverse cardiovascular events (MACE), and safety profiles were analyzed. Baseline characteristics after propensity score matching were well balanced between the two groups. The average age was 61.8 ± 14.6 years for CLTD users, with 59.3% being male. The 3-year MACE occurred in 1.2% of the CLTD group compared with 1.4% of the HCTZ group (hazard ratio 0.91, p = 0.77). For secondary outcomes, cardiovascular mortality was 0.2% in both groups (p = 0.92). Myocardial infarction occurred in 0.3% of CLTD users and 0.4% of HCTZ users (p = 0.65). The incidence of hypokalemia was 19.2% in the CLTD group versus 16.7% in the HCTZ group (p = 0.07). In conclusion, in hypertensive patients, CLTD and HCTZ showed comparable cardiovascular outcomes and safety profiles.

References

Ernst M, Carter B, Goerdt C, Steffensmeier J, Phillips B, Zimmerman M . Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006; 47(3):352-8. DOI: 10.1161/01.HYP.0000203309.07140.d3. View

Ishani A, Hau C, Cushman W, Leatherman S, Lew R, Glassman P . Chlorthalidone vs Hydrochlorothiazide for Hypertension Treatment After Myocardial Infarction or Stroke: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024; 7(5):e2411081. PMC: 11094558. DOI: 10.1001/jamanetworkopen.2024.11081. View

Hripcsak G, Suchard M, Shea S, Chen R, Chan You S, Pratt N . Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension. JAMA Intern Med. 2020; 180(4):542-551. PMC: 7042845. DOI: 10.1001/jamainternmed.2019.7454. View

Siscovick D, Raghunathan T, Psaty B, Koepsell T, Wicklund K, Lin X . Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 1994; 330(26):1852-7. DOI: 10.1056/NEJM199406303302603. View

Gu Q, Burt V, Dillon C, Yoon S . Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation. 2012; 126(17):2105-14. DOI: 10.1161/CIRCULATIONAHA.112.096156. View

Pareek A, Messerli F, Chandurkar N, Dharmadhikari S, Godbole A, Kshirsagar P . Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring. J Am Coll Cardiol. 2016; 67(4):379-389. DOI: 10.1016/j.jacc.2015.10.083. View

Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A . 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal.... J Hypertens. 2023; 41(12):1874-2071. DOI: 10.1097/HJH.0000000000003480. View

Dorsch M, Gillespie B, Erickson S, Bleske B, Weder A . Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011; 57(4):689-94. DOI: 10.1161/HYPERTENSIONAHA.110.161505. View

Unger T, Borghi C, Charchar F, Khan N, Poulter N, Prabhakaran D . 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020; 75(6):1334-1357. DOI: 10.1161/HYPERTENSIONAHA.120.15026. View

10.

Dhalla I, Gomes T, Yao Z, Nagge J, Persaud N, Hellings C . Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. Ann Intern Med. 2013; 158(6):447-55. DOI: 10.7326/0003-4819-158-6-201303190-00004. View

11.

Dineva S, Uzunova K, Pavlova V, Filipova E, Kalinov K, Vekov T . Comparative efficacy and safety of chlorthalidone and hydrochlorothiazide-meta-analysis. J Hum Hypertens. 2019; 33(11):766-774. PMC: 6892412. DOI: 10.1038/s41371-019-0255-2. View

12.

Pierdomenico S, Bucci A, Costantini F, Lapenna D, Cuccurullo F, Mezzetti A . Circadian blood pressure changes and myocardial ischemia in hypertensive patients with coronary artery disease. J Am Coll Cardiol. 1998; 31(7):1627-34. DOI: 10.1016/s0735-1097(98)00163-6. View

13.

Agarwal R, Sinha A, Cramer A, Balmes-Fenwick M, Dickinson J, Ouyang F . Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. N Engl J Med. 2021; 385(27):2507-2519. PMC: 9119310. DOI: 10.1056/NEJMoa2110730. View

14.

Edwards C, Hundemer G, Petrcich W, Canney M, Knoll G, Burns K . Comparison of Clinical Outcomes and Safety Associated With Chlorthalidone vs Hydrochlorothiazide in Older Adults With Varying Levels of Kidney Function. JAMA Netw Open. 2021; 4(9):e2123365. PMC: 8444030. DOI: 10.1001/jamanetworkopen.2021.23365. View

15.

Finkielman J, Schwartz G, Chapman A, Boerwinkle E, Turner S . Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide. Am J Hypertens. 2005; 18(3):398-402. DOI: 10.1016/j.amjhyper.2004.10.021. View

16.

Conde-Martel A, Trullas J, Morales-Rull J, Casado J, Carrera-Izquierdo M, Sanchez-Marteles M . Sex differences in clinical characteristics and outcomes in the CLOROTIC (combining loop with thiazide diuretics for decompensated heart failure) trial. Rev Clin Esp (Barc). 2024; 224(2):67-76. DOI: 10.1016/j.rceng.2023.11.003. View

17.

Rydberg D, Mejyr S, Loikas D, Schenck-Gustafsson K, von Euler M, Malmstrom R . Sex differences in spontaneous reports on adverse drug events for common antihypertensive drugs. Eur J Clin Pharmacol. 2018; 74(9):1165-1173. PMC: 6096710. DOI: 10.1007/s00228-018-2480-y. View

18.

Ishani A, Cushman W, Leatherman S, Lew R, Woods P, Glassman P . Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. N Engl J Med. 2022; 387(26):2401-2410. DOI: 10.1056/NEJMoa2212270. View

19.

Kim H, Lee H, Lee H, Son D, Cho M, Shin S . Korea Hypertension Fact Sheet 2023: analysis of nationwide population-based data with a particular focus on hypertension in special populations. Clin Hypertens. 2024; 30(1):7. PMC: 10905929. DOI: 10.1186/s40885-024-00262-z. View

20.

Seeland U, Regitz-Zagrosek V . Sex and gender differences in cardiovascular drug therapy. Handb Exp Pharmacol. 2012; (214):211-36. DOI: 10.1007/978-3-642-30726-3_11. View